Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Kastritis, E, Gavriatopoulou, M, Roussou, M, Fotiou, D, Ziogas, D C, Migkou, M, Eleutherakis-Papaiakovou, E, Panagiotidis, I, Kanellias, N, Psimenou, E, Papadopoulou, E, Pamboucas, C, Manios, E, Gakiopoulou, H, Ntalianis, A, Tasidou, A, Giannouli, S, Terpos, E, Dimopoulos, M A
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520394/
https://ncbi.nlm.nih.gov/pubmed/28622303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.47
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados